Summary
This prediction ended on 30.03.20 with a price of €8.23. Massive losses of -61.90% were the result for the BUY prediction by melinda. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Adocia | 10.018% | 10.018% | -14.702% | -33.369% |
iShares Core DAX® | 2.821% | -1.953% | 15.071% | 11.862% |
iShares Nasdaq 100 | 5.285% | -5.092% | 29.254% | 40.075% |
iShares Nikkei 225® | 3.687% | -4.221% | 14.286% | 6.629% |
iShares S&P 500 | 3.577% | -2.240% | 25.546% | 38.398% |
According to melinda what are the pros and cons of Adocia for the foreseeable future?
Pros
Could be worthwhile Investment >10% per year
Cons
Comments by melinda for this prediction
In the thread Adocia diskutieren
Secteur Recherche biotechnologique et médicale Agenda 17/07 Publication de résultats
![Logo Adocia Logo Adocia](https://logos.cofisem.fr/FR0011184241.jpg)
Le CA par type de revenus se ventile entre revenus issus de contrats de recherche et de collaboration (96,7%) et revenus de licences (3,3%).
A fin 2017, Adocia dispose d'un portefeuille de 4 produits en phase I/II de développement clinique (BioChaperone Lispro U100 et U200, BioChaperone Combo et HinsBet U100) et de 6 produits en développement préclinique (HinsBet U500, BioChaperone Glucagon, BioChaperone Glargine Dulaglutide, BioChaperone Glargine Liraglutide, BioChaperone Lispro Pramlintide et BioChaperone Lispro Exenatide).
Nombre d'employés
: 129 personnes.
In the thread Trading Adocia
Buy beendet